{"id":"W2263184680","doi":"10.1200/jco.2007.25.18_suppl.5096","title":"The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Renal cell carcinoma; Internal medicine; Nephrectomy; Placebo; Progression-free survival; Surgery; Oncology; Urology; Overall survival; Kidney; Hepatocellular carcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001211793,0.0005031794,0.001091447,0.0001893168,0.000253344,0.0007200042,0.0003503414,0.0004708495,0.002537168],"category_scores_gemma":[0.0008579412,0.000186662,0.0006981705,0.0003579499,0.0004066227,0.0003800305,0.0003064969,0.001553177,0.0003683165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008203643,"about_ca_system_score_gemma":0.001507678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001770164,"about_ca_topic_score_gemma":0.003816988,"domain_scores_codex":[0.9996624,0.0001668184,0.00001545471,0.00006273134,0.00004286728,0.00004966577],"domain_scores_gemma":[0.9992292,0.00009154386,0.0001936277,0.00005827056,0.00006377269,0.0003635348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.897086,0.01085418,0.02095057,0.001300813,0.00210343,0.000337432,0.0001739343,0.003028172,0.007232146,0.0003571006,0.007681143,0.04889513],"study_design_scores_gemma":[0.6868216,0.2194831,0.07510331,0.0001632482,0.002408047,0.0008101587,0.00009019148,0.003060568,0.002926528,0.0003146539,0.008772249,0.00004642048],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994401,0.001572146,0.0001562866,0.0002734669,0.00006522634,0.0005415714,0.001368961,0.00003466703,0.00158669],"genre_scores_gemma":[0.9941182,0.0009003559,0.0003851456,0.0002922915,0.0001407927,0.0004904264,0.002141881,0.000009348957,0.001521483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002537168,"threshold_uncertainty_score":0.008487642,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1603387975336314,"score_gpt":0.4765897460965622,"score_spread":0.3162509485629308,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}